China SXT Pharmaceuticals, Inc. Announces Financial Results for the Six Months Ended September 30, 2020
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENT
This Current Report contains forward-looking statements. All statements contained in this Current Report other than statements of historical fact are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “seek” and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to, the following: the effects of the COVID-19 outbreak, including its impact on the demand for our products; the duration of the COVID-19 outbreak and severity of such outbreak in regions where we operate; the pace of recovery following the COVID-19 outbreak; our ability to implement cost containment and business recovery strategies; the adverse effects of the COVID-19 outbreak on our business or the market price of our ordinary shares, the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this Current Report may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.
You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, we undertake no duty to update any of these forward-looking statements after the date of this Current Report or to conform these statements to actual results or revised expectations.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion and analysis of our results of operations and financial condition should be read together with our unaudited condensed consolidated financial statements and the notes thereto and other financial information, which are included elsewhere in this Form 6-K. Our unaudited financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”). In addition, our unaudited financial statements and the financial information included in this Form 6-K reflect our organizational transactions and have been prepared as if our current corporate structure had been in place throughout the relevant periods.
This section contains forward-looking statements. These forward-looking statements are subject to various factors, risks and uncertainties that could cause actual results to differ materially from those reflected in these forward-looking statements. Further, as a result of these factors, risks and uncertainties, the forward-looking events may not occur. Relevant factors, risks and uncertainties include, but are not limited to, those discussed in the section entitled “Business,” “Risk Factors” and elsewhere in this Form 6-K. Readers are cautioned not to place undue reliance on forward-looking statements, which reflect management’s beliefs and opinions as of the date of this Form 6-K. We are not obligated to publicly update or revise any forward-looking statements, whether as a result of new Information, future events or otherwise. See “Special Note Regarding Forward-Looking Statements.”
Key Factors Affecting Our Results of Operation
Working capital required to implement our business plan will most likely be provided by funds obtained through offerings of our equity, debt, debt-linked securities, and/or equity-linked securities, and revenues generated by us. No assurance can be given that we will have revenues sufficient to support and sustain our operations or that we would be able to obtain equity/debt financing in the current economic environment. If we do not have sufficient working capital and are unable to generate sufficient revenues or raise additional funds, we may delay the completion of or significantly reduce the scope of our current business plan; delay some of our development and clinical or marketing efforts; postpone the hiring of new personnel; or, under certain dire financial circumstances, substantially curtail or cease our operations.
Our past operating results are not an accurate indication of the lines of business we are principally engaged in currently. Thus, you should consider our future prospects in light of the risks and uncertainties experienced by early-stage companies in evolving markets rather than typical companies of our age. Some of these risks and uncertainties relate to our ability to:
Results of Operations for the Six Months Ended September 30, 2020 Compared to September 30, 2019
We generated revenues primarily from manufacture and sales of four types of traditional Chinese medicine pieces (the “TCMP”) products: Advanced TCMP, Fine TCMP, Regular TCMP, and TCM Homologous Supplements (“TCMHS”) products. TCMHS is a classification of health-supporting food used traditionally in China as TCM but are also consumed as food, which has been developed and commercialized in April 2019. As compared with the six months ended September 30, 2020, our total revenues increased by $645,354, or 20% for the six months ended September 30, 2020. The increase was primarily due to the increase in sales of Advanced TCMP products and TCMHS products and partly offset by the decrease in the sales of Fine TCMP products and Regular TCMP products.
The following table sets forth the breakdown of revenues by categories for the six months ended September 30, 2020 and 2019 presented:
Advanced TCMP is comprised of nine Directly Oral TCMP products (the “Directly-Oral-TCMP”) and nine After-soaking-oral TCMP products (the “After-Soaking-Oral-TCMP”). Both Directly Oral TCMP and After-soaking-oral TCMP are new types of advanced TCMP.
Revenue from advanced TCMP accounted for 44% and 34% of revenue recognized during the six months ended September 30, 2020 and 2019, respectively. As compared with the six months ended September 30, 2019, our revenue generated from advanced TCMP increased by $596,172, or 54% for the six months ended September 30, 2020. The increase was primarily due to the company’s plan to shift from low margin Regular TCMPs and to focus more on the business of high margin Fine and Advanced TCMPs.
We currently produce over 15 fine TCMP products for drug stores and hospitals. Our fine TCMP products are manufactured manually from only high-quality authentic ingredients derived from their region of origin.
Revenue from fine TCMP accounted for 6% and 20% of revenue recognized during the six months ended September 30, 2020 and 2019. As compared with the six months ended September 30, 2019, our revenue from generated from fine TCMP decreased by $419,983, or 64% for the six months ended September 30, 2020. The decrease was primarily attributable to the effect of COVID-19 outbreak in China on the operation of pharmaceutical stores, which were the main sale channel for fine TCMP products.
We currently manufacture 430 regular TCMP products listed on China Pharmacopoeia (version 2015) Part I for hospitals and drug store in treatment of various diseases or serving as dietary supplements.
Revenue from regular TCMP accounted for 21% and 40% of revenue recognized during the six months ended September 30, 2020 and 2019, respectively. Revenue from regular TCMP products decreased by $479,347, or 37%, to $818,627 for the six months ended September 30, 2020 from $1,297,974 for the six months ended September 30, 2019. Decrease in revenue from Regular TCMP products is consistent with the effect of the effect of COVID-19 outbreak in China and the company’s plan to shift from low margin Regular TCMPs and to focus more on the business of high margin Fine and Advanced TCMPs.
TCMHS Solid Beverages
Four solid beverage products as part of the Company’s TCMHS products were developed and commercially launched in April 2019 and generated a revenue of $1,108,883 and $160,371 for the six months ended September 30, 2019, respectively, representing an increase of $948,512.
Cost of revenues primarily include cost of materials, direct labors, overhead, and other related incidental expenses that are directly attributable to the Company’s principal operations. Total cost of revenue decreased by $ 336,197, or 24%, to $1,039,565 for the six months ended September 30, 2020 from $1,375,762 for the six months ended September 30, 2019. The decrease of cost of revenues was mainly due to the decrease of the sales of our products.
Gross profit increased by $ 981,551, or 53%, to $2,820,936 for the six months ended September 30, 2020 from $1,839,385 for the six months ended September 30, 2019. Gross margin was 73.1% for the six months ended September 30, 2020, compared to 57.2% for the six months ended September 30, 2019. The increase in gross margin was mainly due to the increase of gross margin of TCMHS products and Regular TCMP products and offset by the decrease of gross margin of Fine TCMP products.
Selling expenses primarily consisted of sales staff payroll and welfare expenses, travelling expenses, advertisement expenses, distribution expenses. Selling expenses decrease from $774,253 for the six months ended September 30, 2019 to $704,558 for the six months ended September 30, 2020, representing a decrease of $69,695, or 9%.
General and administrative expenses primarily consisted of staff payroll and welfare expenses, research and development expenses, entertainment expenses, travelling expenses, depreciation and amortization expenses for administrative purposes, and office supply expenses. General and administrative expenses decreased from $ 1,285,885 for the six months ended September 30, 2019 to $952,568 for the six months ended September 30, 2020, representing a decrease of $333,317, or 26%.
The decreases in selling expenses and general and administrative expenses were mainly due to the Company’s efforts in cost control.
Operating income increased $1,384,563 from an operating loss of $220,753 for the six months ended September 30, 2019 to an operating income of $1,163,810 for the six months ended September 30, 2020.
Income before income taxes
Interest income (expenses) for the six months ended September 30, 2020 mainly consists of accretion of finance cost and interest expense of the issuance and forbearance of Convertible Notes issued on April 16, 2019. For the six months ended September 30, 2020, the company record amortization of issuance cost and debt discount of $184,587 and Convertible Notes interest expense of $298,145.
Other income (expense) increased $2,584,946 from a loss of $2,132,482 for the six months ended September 30, 2019 to an income of $452,464 for the six months ended September 30, 2020.
Income before income taxes increased $3,969,509 from a loss of $2,353,235 for the six months ended September 30, 2019 to an income of $1,616,274 for the six months ended September 30, 2020.
Income tax expense represented current and deferred income tax expenses derived from income before taxes generated by Jiangsu Suxuantang Pharmaceutical Co., Ltd (“Suxuantang”), the variable interest entity of the Company. As compared with the six months ended September 30, 2019, the income tax expense for the six months ended September 30, 2020 increased by $240,182. Income tax expense for the six months ended September 30, 2020 consists of current income tax of $143,534 and deferred tax benefit of $91,482.
As a result of the foregoing, net income for the six months ended September 30, 2020 was $1,381,258, representing an increase of $3,729,327 from net loss of $2,348,069 for the six months ended September 30, 2019.
Liquidity and Capital Resources
To date, we have financed our operations primarily through shareholder capital contributions, shareholder loans, convertible notes, and cash flow from operations. As a result of our total activities, we had cash and cash equivalents of $10,353,474 and $7,287,032 as of September 30, 2020 and March 31, 2020, respectively. We primarily hold our excess unrestricted cash in short-term interest-bearing bank accounts at financial institutions. As of September 30, 2020, we had current liabilities balance of $5,506,455, which the Company expects to repay within 1 year. With the current cash and cash equivalents and anticipated cash flows from operating activities, we believe that our cash position is sufficient to meet our liquidity needs for at least the next 12 months.
Cash Flow in Operating Activities
For the six months ended September 30, 2020 net cash used in operating activities was $333,508, as compared to net cash used operating activities of $2,023,834 for the six months ended September 30, 2019, representing an increase of $1,690,326. The increase in net cash provided by operating activities primarily resulted from the change of following accounts:
And offset by the change of following accounts:
Cash Flow in Investing Activities
We had net cash provided by investing activities of $2,738,048, for the six months ended September 30, 2020, which primarily consisted of purchase of property and equipment of $4,931, capital expenditure in construction in process of $114,286, and a collection of receivables from Huangshan Panjie Investment Management Co., Ltd. of $2,857,265.
We had net cash used in investing activities of $5,487,867, for the six months ended September 30, 2019, which primarily consisted of purchase of property and equipment of $123,543, capital expenditure in construction in process of $250,178, loan receivable from RH Holdings Management (HK) Limited of $1,500,000, and a receivable from Huangshan Panjie Investment Management Co., Ltd. of $3,614,146.
Cash Flow in Financing Activities
For the six months ended September 30, 2020, the net cash provided by financing activities was $274,497, which was primarily attributable to repayment of principal and interest of Convertible Notes of $26,378, amounts received from related parties of $323,080 and payment of the bank borrowings of $22,205.
For the six months ended September 30, 2019, the net cash provided by financing activities was $6,913,556, which was primarily attributable to net proceeds from the convertible notes of $8,358,950 (gross proceeds of $10,000,000 and debt issuance cost of $1,641,050), repayment of principal and interest of Convertible Notes of $869,565, repayment of amounts due to related parties of $610,204, and net proceeds from bank borrowings of $34,375.
The Convertible Notes
On April 16, 2019, the company entered into a Securities Purchase Agreement with certain unaffiliated institutional investors relating to a private placement by the company of (1) Senior Convertible Notes (the “Convertible Notes”) in the aggregate principal amount of $15 million, consisting of (i) a Series A Note in the principal amount of $ 10 million , and (ii) a Series B Note in the principal amount of $ 5 million and (2) warrants (the “Warrants”) to purchase such amount of shares of the company’s ordinary shares equal to 50% of the shares issuable upon conversion of the Notes, exercisable for a period of five years at an initial exercise price of $8.38, for consideration consisting of (i) a cash payment of $10,000,000, and (ii) a secured promissory note payable by the Investors to the Company in the principal amount of $5 million. All amounts outstanding under the Notes were mature and due and payable on or before October 2, 2020.
Material Terms of the Convertible Notes:
Entry into Forbearance Agreements in Connection with the Event of Default Redemption Notices
On July 23 and 29, 2019, the company received from the investors an Event of Default Redemption Notice claimed that the company failed to timely make the instalment payment and elected to effect the redemption of $14,318,462.62 comprising in aggregate the entire principal amount, accrued and unpaid Interest. In addition, demand for the company to purchase the Series A Warrant issued for the Event of Default Black Scholes Value of not less than $1,208,384.07 was made.
On December 13, 2019, after negotiation with the Investors, the company entered into certain Forbearance and Amendment Agreements with each Investor and agreed to redeem the Series A Notes for an aggregate redemption price of $10,939,410 in installments as set forth in the Forbearance Agreement. Concurrently with the execution of the Forbearance Agreement, the Investors and the Company have entered into the Lock-Up Agreements, Leak-Out Agreements and Mutual Releases.
Material Terms of the Agreements
Upon the execution of the Forbearance Agreements, the Investor shall net all Restricted Principal (as defined in Series B Note) outstanding under the Series B Note against the amounts outstanding under the Investor Note, after which the Investor Note, the Series B Note and the Series B Warrant shall no longer remain outstanding.
The Investors agreed, among other things, to the following:
According to the Forbearance Agreements, the Company issued and delivered 4,000,000 un-legended Pre-Delivery Shares into the investor’s custodian’s account as collateral in December 2019. The Company has made full payment of the forbearance redemption amounts in accordance with the Forbearance Agreements to the investors. Upon full payment, each investor returned 2,000,000 Ordinary Shares to the Company, which served as security for the Company’s obligations owed to the investors. To date, the Convertible Notes were fully converted to the Company’s shares, and the Company has cancelled the 4,000,000 Ordinary Shares by November 2, 2020.
Please refer to Note 11 of our Condensed Consolidated Financial Statements included in this Form 6-K for details of accounting of the Convertible Notes.
Off-Balance Sheet Arrangements
On April 23, 2019, the Company entered into a financial guarantee agreement with Jiangsu Changjiang Commercial Bank to be the guarantor of Taizhou Jiutian Pharmaceutical Co. Ltd.’s bank borrowing of $441,852 (equivalent of RMB 3,000,000) for one-year period. On May 8, 2019 the Company entered a financial guarantee agreement with Bank of Nanjing to be the guarantor of Taizhou Jiutian Pharmaceutical Co. Ltd.’s borrowing of $515,494 (equivalent of RMB 3,500,000) for a one-year period. The Company is obliged to pay on behalf the related party the principal, interest, penalty and other expenses if Taizhou Jiutian Pharmaceutical Co. Ltd. defaults in payment. The Company did not charge financial guarantee fees over Taizhou Jiutian Pharmaceutical Co. Ltd.
On April 23, 2020, the Company signed a financial guarantee agreement with Jiangsu Changjiang Commercial Bank for Taizhou Jiutian Pharmaceutical Co. Ltd. in borrowing of $427,124 (equivalent of RMB 2,900,000) for one-year period. On May 18, 2020 the Company signed a financial guarantee agreement with Bank of Nanjing for Taizhou
Jiutian Pharmaceutical Co. Ltd. in borrowing of $500,766 (equivalent of RMB 3,400,000) for a one-year period. The Company is obliged to pay on behalf the related party the principal, interest, penalty and other expenses if Taizhou Jiutian Pharmaceutical Co. Ltd. defaults in payment.
The Company had the following operating lease commitment as of September 30, 2020:
Except for the guarantee and commitment listed above, the Company does not have any other off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.
We do not believe our business and operations have been materially affected by inflation.
Related Parties and Material Related Party Transactions
Please refer to Note 15 of our Condensed Consolidated Financial Statements included in this Form 6-K for details of related parties and material related party transactions.
Critical Accounting Policies
Please refer to Note 2 of our Condensed Consolidated Financial Statements included in Form 6-K or details of our critical accounting policies.
On November 24, 2020, China SXT Pharmaceuticals, Inc. (the “Company”) entered into certain securities purchase agreement (the “SPA”) with Xing Yuan, a non-affiliate non-U.S. person (the “Investor”), pursuant to which Mr. Yuan agreed to purchase 12,000,000 ordinary shares (the “Shares”) of the Company, par value $0.001 per share (the “Ordinary Shares”) at a per share purchase price of $0.60. The gross proceeds of this transaction are $7,200,000.
On the same date, Mr. Yuan also entered into certain voting agreement (the “Voting Agreement”) with Mr. Feng Zhou, who beneficially owns 8,500,000 Ordinary Shares, representing approximately 13.68% of the total voting power as of the date of this report. According to the Voting Agreement, Mr. Yuan irrevocably grants a power of attorney to, and entrust Mr. Zhou, for the maximum period of time permitted by law, with all of Mr. Yuan’s voting rights as a shareholder of the Company, including without limitation, in connection with the election of directors and approval of all corporate transactions which requires the approval of the Company’s shareholders.
In connection with this private placement and the recent resignation of the board member, Mr. Tulin Lu, the board of directors of the Company appointed Mr. Yuan as a director to fill in the vacancy created by the resignation of Mr. Lu effective upon closing of the offering contemplated by the SPA, provided that, Mr. Yuan will cease to be a member of the board once he holds less than 1,200,000 Ordinary Shares.
As of date of this report, this private placement has not been closed as the Investor has not delivered the purchase price yet.
Settlement Agreement with the Placement Agent
By November 2, 2020, the Series A Notes issued on May 2, 2019 in connection with the private placement have been fully converted. FT Global Capital, Inc. (“FT Global”), the placement agent for such private placement demanded that additional warrant should be issued to Mr. Jian Ke, the president of FT Global according to certain placement agency agreement entered by and between the Company and it on May 2, 2019. After friendly negotiation, the Company and FT Global agreed to settle this claim and signed certain settlement agreement on January 18, 2021. Pursuant to such settlement agreement, the Company issued a new warrant to Mr. Ke for purchase of 1,000,000 Ordinary Shares on the same terms and conditions as the warrants issued to Mr. Ke on May 2, 2019.
The forms of the settlement agreement and the new warrant are filed as Exhibits 4.1 and 4.2 to this Current Report on Form 6-K and such documents are incorporated herein by reference. The foregoing is only a brief description of the material terms of the settlement agreement and the warrant, and does not purport to be a complete description of the rights and obligations of the parties thereunder and is qualified in its entirety by reference to such exhibits.
Financial Statements and Exhibits.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January 28, 2021